1082555-06-3

Basic information

• Product Name: 2-(3-chlorophenyl) propan-1-amine
• Synonyms: 2-(3-chlorophenyl) propan-1-amine
• CAS NO: 1082555-06-3
• Molecular Weight: 169.654
• Mol File: 1082555-06-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 234.0±15.0 °C(Predicted)
• Density: 1.093±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-(3-chlorophenyl) propan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-chlorophenyl) propan-1-amine(1082555-06-3)
• EPA Substance Registry System: 2-(3-chlorophenyl) propan-1-amine(1082555-06-3)

Safety Data

• Hazardous Substances Data: 1082555-06-3(Hazardous Substances Data)

Usage

General Description

2-(3-chlorophenyl) propan-1-amine, also known as 3-CPA, is a chemical compound with the molecular formula C9H12ClN. It is a psychoactive drug and has been used in scientific research as a serotonin-norepinephrine-dopamine releasing agent with similar effects to amphetamine. 3-CPA is a phenethylamine derivative and is structurally similar to the psychoactive drug MDMA. It is classified as a controlled substance in some jurisdictions due to its potential for abuse and dependence. As with other psychoactive substances, 3-CPA can have both stimulant and hallucinogenic effects, and its use carries a risk of adverse effects on both physical and mental health.

Upstream product

• 103040-42-2 Methyl-2-(3-chlorophenyl) propanoate 
• 63489-71-4 2-(3-chlorophenyl) propan-1-ol 
• 1638587-52-6 2-(3-chlorophenyl) propyl methanesulfonate 
• 1616729-46-4 2-(3-chlorophenyl) propyl phthalimide 
• 947732-85-6 3-chloro-α-methylphenylacetaldehyde 
• 14161-84-3 2-(3-chlorophenyl) propanoic acid 
• 65487-35-6 2-(3-chlorophenyl) propanamide 
• 1878-65-5 3-chlorophenylacetic acid 
• 53088-68-9 methyl 3-chlorophenylacetate 
• 947383-49-5 (E)-1-chloro-3-(1-nitroprop-1-en-2-yl)benzene 
• 1712-71-6 3-chloro-α-methylstyrene 
• 14271-35-3 rac-2-(3-chlorophenyl)propanenitrile 
• 1529-41-5 3-chloro-benzeneacetonitrile 

Downstream Products

• 616201-80-0 (+/-)-Lorcaserin 
• 1431697-94-7 (±)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride 
• 1616729-45-3 2-(3-chlorophenyl)-N-(2,2-dimethoxyethyl)propan-1-amine 
• 1440519-51-6 [2-(3-chlorophenyl)propyl]carbamic acid methyl ester 

Relevant articles and documents

Light-Enabled Enantiodivergence: Stereospecific Reduction of Activated Alkenes Using a Single Organocatalyst Enantiomer

Light-enabled enantiodivergence is demonstrated in which the alkene substrate configuration is manipulated (E → Z) prior to organocatalytic reduction with a chiral thiourea and Hantzsch ester. This allows stereodivergent reduction to be regulated at the substrate level with high fidelity and mitigates the need for a second, enantiomeric catalyst (up to 93:07 and 95:5 er). The synthetic utility of this strategy has been demonstrated in the synthesis of the weight-loss drug (R)-Lorcaserin (Belviq) and a potent AMPA modulator.

NOVEL SYNTHETIC PROCESS TO 8-CHLORO-1-METHYL-BENZO[D]AZEPINE, NOVEL INTERMEDIATES AND THE PRODUCTION THEREOF

The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopure (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d] azepine or its (S)-enantiomer, in order to avoid or overcome chemical optical resolution.

Structure-activity relationship of N,N′-disubstituted pyrimidinetriones as CaV1.3 calcium channel-selective antagonists for Parkinson's disease

CaV1.3 L-type calcium channels (LTCCs) have been a potential target for Parkinson's disease since calcium ion influx through the channel was implicated in the generation of mitochondrial oxidative stress, causing cell death in the dopaminergic neurons. Selective inhibition of CaV1.3 over other LTCC isoforms, especially CaV1.2, is critical to minimize potential side effects. We recently identified pyrimidinetriones (PYTs) as a CaV1.3-selective scaffold; here we report the structure-activity relationship of PYTs with both CaV1.3 and CaV1.2 LTCCs. By variation of the substituents on the cyclopentyl and arylalkyl groups of PYT, SAR studies allowed characterization of the CaV1.3 and Ca V1.2 LTCCs binding sites. The SAR also identified four important moieties that either retain selectivity or enhance binding affinity. Our study represents a significant enhancement of the SAR of PYTs at CaV1.3 and CaV1.2 LTCCs and highlights several advances in the lead optimization and diversification of this family of compounds for drug development.